Product information and disease descriptionPlace of product in therapy
Approaches to treatment
20 evidence topics · 10 sources
Other product development or post-marketing obligations required by the FDA
No evidence found.
Tirabrutinib
Primary central nervous system lymphoma
- Manufacturer
- Deciphera Pharmaceuticals
- Regulatory submission
- NDA submitted December 2025
- Last updated